Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Eli Lilly Introduced First and Only Zepbound® for Obstructive Sleep Apnoea in Adults with Obesity
Eli Lilly has announced the FDA approval of Zepbound® (tirzepatide), the first and only prescription medication for treating moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity. This innovative treatment is designed to be used alongside a reduced-calorie diet and increased physical activity.
Pfizer Launches First-Line Treatment for Mutant Metastatic Colourectal Cancer
Pfizer has introduced BRAFTOVI® (encorafenib), in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (comprising fluorouracil, leucovorin, and oxaliplatin), as a first-line treatment for patients with metastatic colourectal cancer (mCRC) harbouring a BRAF V600E mutation.
HUTCHMED Discovers Novel ORPATHYS® and TAGRISSO® Combination for Non‑small Cell Lung Cancer
HUTCHMED has introduced the groundbreaking combination therapy of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET amplification, following disease progression on EGFR inhibitor therapy.
Sanofi Introduces Breakthrough Tolebrutinib for Non-relapsing Secondary Progressive Multiple Sclerosis
Sanofi has introduced tolebrutinib, an investigational treatment for adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Stoke Therapeutics Introduced Breakthrough Zorevunersen for the Treatment of Dravet Syndrome
Stoke Therapeutics has introduced zorevunersen, a groundbreaking treatment for Dravet syndrome, targeting cases with confirmed SCN1A gene mutations that are not associated with gain-of-function.
Merck Develops Novel Sacituzumab Tirumotecan for Advanced NSCLC Treatment
Merck has developed a groundbreaking treatment, sacituzumab tirumotecan (sac-TMT), for patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations (exon 19 deletion [19del] or exon 21 L858R).
InxMed Unveils Lfebemtinib for First-Line Non-Small Cell Lung Cancer (NSCLC) Treatment with KRAS G12C Mutation
InxMed has introduced Ifebemtinib for the first-line (1L) treatment of non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, in combination with garsorasib, a targeted inhibitor specifically designed for the KRAS G12C mutation.
Huahui Health Launches Novel Libevitug (HH-003) for Treatment of Chronic Hepatitis D Virus Infection
Huahui Health has introduced a novel investigational drug candidate, Libevitug (HH-003), aimed at treating chronic hepatitis D virus (HDV) infection. This anti-PreS1 human monoclonal antibody is designed to target and neutralise both hepatitis B virus (HBV) and HDV.
Syndax Launches Revuforj® for Relapsed/Refractory Acute Leukemia Treatment
Syndax Pharmaceuticals has launched Revuforj® (revumenib), the first and only menin inhibitor for treating relapsed or refractory (R/R) acute leukaemia with a lysine methyltransferase 2A (KMT2A) gene translocation in adults and paediatric patients aged one year and older.
Johnson & Johnson Unveils First and Only Nipocalimab for the Treatment of Sjögren’s disease
Johnson & Johnson has introduced nipocalimab as the first investigational therapy for adults with moderate-to-severe Sjögren’s disease (SjD), a chronic autoimmune condition affecting approximately four million people globally, predominantly women.
